Apogee Therapeutics, Inc.
APGE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $400 | $0 | $0 | $0 |
| Gross Profit | -$400 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $54,178 | $55,703 | $46,387 | $60,229 |
| G&A Expenses | $17,100 | $17,137 | $16,566 | $15,652 |
| SG&A Expenses | $17,100 | $17,137 | $16,566 | $15,652 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$400 | $325 | $143 | $0 |
| Operating Expenses | $70,878 | $73,165 | $63,096 | $75,881 |
| Operating Income | -$71,278 | -$73,165 | -$63,096 | -$75,881 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6,318 | $7,141 | $7,840 | $8,681 |
| Pre-Tax Income | -$64,960 | -$66,024 | -$55,256 | -$67,200 |
| Tax Expense | $61 | $72 | $83 | $18 |
| Net Income | -$65,021 | -$66,096 | -$55,339 | -$67,218 |
| % Margin | – | – | – | – |
| EPS | -1.11 | -1.13 | -0.95 | -1.22 |
| % Growth | 1.8% | -18.9% | 22.1% | – |
| EPS Diluted | -1.11 | -1.13 | -0.95 | -1.22 |
| Weighted Avg Shares Out | 58,774 | 58,428 | 58,195 | 55,194 |
| Weighted Avg Shares Out Dil | 58,774 | 58,428 | 58,195 | 55,194 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,318 | $7,141 | $7,840 | $8,681 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $400 | $399 | $207 | $76 |
| EBITDA | -$64,560 | -$72,766 | -$62,889 | -$75,805 |
| % Margin | – | – | – | – |